The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
#IACH2024: Lymphoma and chronic lymphocytic leukemia
To update you on the exciting content presented at the 7th Annual Meeting of the International Academy of Clinical Hematology (IACH), we have collated our social media coverage. Catch up with our posts relating to lymphoma and chronic lymphocytic leukemia below.
CONGRESS | @TheIACH #IACH2024 | PRESENTATION
— Lymphoma Hub (@lymphomahub) September 21, 2024
Amer Beitinjaneh @abeitin @univmiami @SylvesterCancer discusses the management of patients with R/R mantle cell lymphoma.
They highlight the role of BTK inhibitors, CAR T-cell therapies, transplantation, and novel therapies in the R/R… pic.twitter.com/xgqb7hKy33
CONGRESS | @TheIACH #IACH2024 | PRESENTATION
— Lymphoma Hub (@lymphomahub) September 21, 2024
Madiha Iqbal @MadihaIqbal13 @MayoClinic provides an update on the first-line management of patients with mantle cell lymphoma
They discuss the optimization of chemoimmunotherapy, the use of targeted agents such as BTK inhibitors, the… pic.twitter.com/RiVOSWzgDB
CONGRESS | @TheIACH #IACH2024 | PRESENTATION
— Lymphoma Hub (@lymphomahub) September 20, 2024
Christiane Pott, @UKSH_KI_HL, shares insights on MRD assessment in mantle cell #lymphoma. They discuss a treatment approach that involves identifying high-risk gene signatures, making early treatment adjustments, and determining which… pic.twitter.com/wqvAL84TXT
CONGRESS | @TheIACH #IACH2024 | POSTER
— Lymphoma Hub (@lymphomahub) September 20, 2024
Tamar Tadmor @TadmorTamar Bnai Zion Medical Center, presents an overview of the phase III BELLWAVE-011 trial.
The BELLWAVE-011 trial will assess the safety and efficacy of nemtabrutinib vs investigator’s choice of ibrutinib or acalabrutinib… pic.twitter.com/rPbIbffxk3
CONGRESS | @TheIACH #IACH2024 | POSTER
— Lymphoma Hub (@lymphomahub) September 20, 2024
Vasile Musteata, N. Testemitanu State University of Medicine and Pharmacy, shares findings from a single-center analysis of the outcomes of patients with Hodgkin lymphoma treated with combined chemotherapy.
The complete response and partial… pic.twitter.com/00FJFqzEkq
CONGRESS | @TheIACH #IACH2024 | POSTER
— Lymphoma Hub (@lymphomahub) September 20, 2024
Vasile Musteata, N. Testemitanu State University of Medicine and Pharmacy, presents results from an analysis of 84 patients with generalized nodal NHL.
70% of patients achieved a complete response following treatment with immunochemotherapy… pic.twitter.com/KmBbeUqvby
CONGRESS | @TheIACH #IACH2024 | PRESENTATION
— Lymphoma Hub (@lymphomahub) September 20, 2024
Olivier Tournilhac @CHUClermontFd provides an overview of transplantation and cellular therapies in patients with CLL.
They discuss the use of transplantation and CAR T-cell therapies in patients with CLL, particularly in BTKi/BCL2i… pic.twitter.com/C6adFDF3uZ
CONGRESS | @TheIACH #IACH2024 | PRESENTATION
— Lymphoma Hub (@lymphomahub) September 20, 2024
Farrukh Awan @awandoc @UTSWMedCenter discusses first-line therapy in patients with CLL.
They highlight the role of BTK inhibitors, anti-CD20 antibodies, BCL2 inhibitors, and potential combination therapies in patients with CLL, and… pic.twitter.com/6Q9F56MIuT
CONGRESS | @TheIACH #IACH2024 | PRESENTATION
— Lymphoma Hub (@lymphomahub) September 19, 2024
Andrew Davies @AndyD1036 @UHSFT shares insights on bispecific antibodies in patients with DLBCL.
They highlight key clinical trial data and discuss potential advantages over CAR T-cell therapies.
Follow our live feed for more updates:… pic.twitter.com/MgQusxxpgm
CONGRESS | @TheIACH #IACH2024 | PRESENTATION
— Lymphoma Hub (@lymphomahub) September 19, 2024
Mariana Bastos-Oreiro @DrBastosOreiroM Gregorio Marañón Hospital, Madrid, provides an overview of CAR T-cell therapies for patients with DLBCL.
They discuss efficacy and safety results from clinical trials and real-world studies, and… pic.twitter.com/1fWBaxWpvk
CONGRESS | @TheIACH #IACH2024 | PRESENTATION
— Lymphoma Hub (@lymphomahub) September 19, 2024
Andrew Davies @AndyD1036 @UHSFT discusses first-line treatment in patients with DLBCL.
They highlight advancements in disease classification and the evolving role of therapies targeting cell surface markers.
Follow our live feed for… pic.twitter.com/5gEO6lz2UX
CONGRESS | @TheIACH #IACH2024 | PRESENTATION
— Lymphoma Hub (@lymphomahub) September 19, 2024
Nilanjan Ghosh @NGhoshMD @LevineCancer provides an overview of salvage therapy in patients with R/R Hodgkin lymphoma.
They discuss salvage therapy options, and highlight some of the key considerations for treatment selection in this… pic.twitter.com/2qsHYwcmFw
CONGRESS | @TheIACH #IACH2024 | PRESENTATION
— Lymphoma Hub (@lymphomahub) September 19, 2024
Graham Collins @graham74GC @OUHospitals @OxfordCancer examines first-line treatment in older/unfit patients with Hodgkin lymphoma.
They highlight some of the key challenges and considerations, and discuss a potential treatment… pic.twitter.com/EglAs1T4qb
CONGRESS | @TheIACH #IACH2024 | PRESENTATION
— Lymphoma Hub (@lymphomahub) September 19, 2024
Farrukh Awan @awandoc @UTSWMedCenter discusses first-line treatment in young/fit patients with Hodgkin lymphoma (HL).
They provide an overview of treatment options for patients with advanced-stage and early-stage HL, and highlight key… pic.twitter.com/vTDjiZZOpB
CONGRESS #EHA2024 | Poster | Jan Burger @MDAndersonNews reports phase 2 study of time-limited treatment with acalabrutinib plus obinutuzumab in pts with treatment-naïve CLL. N=28, estimated 2 yr PFS & OS were 95.8%. ORR=100%, CR=67%, PR=33% at end of therapy. BM infiltration by… pic.twitter.com/hBJiEE4ELA
— Lymphoma Hub (@lymphomahub) June 15, 2024
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
